Fig. 2From: Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibodyGenomic landscape of 59 patients with melanoma. NRAS mutation and CDKN2A deletion were the most commonly detected mutations, with no statistically significant difference between responder and non-responder groups. Neither BRAFV600 nor KIT mutational status affected treatment outcome of immunotherapyBack to article page